A clinical stage biotech focused on preventing cancer recurrence through a next-generation proprietary immunotherapy targeting colorectal cancer. The allogeneic therapeutic platform aims to enhance immune system education using advanced multiomics technologies while maintaining cost-effectiveness and supply control.